97 results about "Castration Resistance" patented technology

The present disclosure relates to a method of treating prostate specific membrane antigen (PSMA) positive progressive metastatic castration resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA binding radioligand therapy (RLT) agent, preferably [177Lu] Lu-PSMA-617 (lutetium (177Lu) vevovortitide Tailaracetam), to a taxane primarily treated patient whose disease progresses after receiving a second generation ARPI.

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and / or castrate-resistant prostate cancer, in subjects in need thereof.

The invention relates to the technical field of medical image processing, in particular to a tumor prognosis risk prediction method based on multi-modal medical image fusion, which comprises the following steps: firstly, acquiring patient data, and preprocessing the patient data; the patient data comprises an MRI image and a WSI image of the prostate cancer patient; then, MRI image features and WSI image features are respectively extracted from the preprocessed data; next, the MRI image features and the WSI image features are fused, and fused features are obtained; and finally, inputting the fusion features into a deep learning prediction model, and outputting a risk probability value that the patient develops into CRPC. The tumor prognosis risk prediction method based on multi-modal medical image fusion provided by the invention can effectively predict the risk of prostate cancer patients developing into castration-resistant prostate cancer after androgen deprivation treatment.

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer and methods of increasing overall survival thereof.

The present invention belongs to the field of biomedicine technology, and relates to the application of the Lnc-FLJ gene in the treatment of castration-resistant prostate cancer. The application of the Lnc-FLJ gene inhibitor in the preparation of prostate cancer drugs. The present invention discovered for the first time that Lnc-FLJ can inhibit the proliferation and autophagy of castration-resistant prostate cancer. Lnc-FLJ is more highly expressed in castration-resistant prostate cancer cells and prostate cancer tissues with higher malignancy. Inhibiting Lnc-FLJ can inhibit the occurrence and development of castration-resistant prostate cancer. The preparation of Lnc-FLJ small molecule inhibitor shRNA is used to treat castration-resistant prostate cancer and cancer insensitive to enzalutamide, thereby inhibiting the AR signaling pathway. The present invention provides new ideas for further studying the pathogenesis of castration-resistant prostate cancer and the function of the Lnc-FLJ gene, and provides a new direction for the development of castration-resistant prostate cancer drugs.

Methods and compositions for treatment of prostate cancers, such as androgen receptor (AR) deficient and androgen receptor (AR) low cancers, are disclosed. The methods include administration of an agent that inhibits activity of eIF4F or an agent that disrupts the eIF4F translation-initiation complex (composed of eIF4E, eIF4A, and eIF4G).

The invention provides a dalotamide monophosphate compound shown as a formula I or a pharmaceutically acceptable salt thereof, and n is an integer of 1-3, preferably an integer of 1-2. The compound provided by the invention can be used for preparing medicines for treating adult patients with non-metastatic castration-resistant prostate cancer with high metastasis risk.

The present disclosure provides methods for treating prostate cancer or metastatic castration-resistant prostate cancer, reducing the severity of prostate cancer or metastatic castration-resistant prostate cancer, or inhibiting the growth of prostate cancer or metastatic castration-resistant prostate cancer. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody, or antigen-binding fragment thereof, that specifically binds to prostate specific membrane antigen (PSMA) and CD28, as a monotherapy or in combination with an anti-PD1 antibody.

The invention belongs to the technical field of cancer treatment, and discloses a method for inhibiting castration-resistant prostate cancer proliferation and metastasis by promoting collagen degradation through targeting ADAMTS1. According to the method, ADAMTS1 is determined to be a mechanism key point for linking epigenetic reprogramming with biomechanical microenvironment destruction. The ADAMTS1 is reactivated to degrade a collagen-rich matrix, the FAK / MAPK mechanical transduction signaling pathway is inhibited, and the epithelial-mesenchymal transition (EMT) is reversed. The strategy not only achieves more than 90% of tumor inhibition effect, but also exhausts immunosuppressive macrophages and regulatory T cells to reverse immunosuppression by enhancing toxic CD8 + T cell infiltration. The research determines that epigenetic-ECM coevolution is a symbolic feature of CRPC, and provides a reasonably designed combination therapy for treating castration-resistant prostate cancer.

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None

The present invention relates to a composition for the treatment of castration resistant prostate cancer, the composition comprising (i) a first active ingredient comprising a CDK9 degrading agent; and (ii) a second active ingredient, wherein the second active ingredient comprises olaparib. The effects of inhibiting tumor cell proliferation and promoting cell apoptosis of the composition are obviously higher than those of a single drug under the same dosage.

This is a method for treating prostate cancer. Specifically, it involves the use of the compound shown in Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a drug for treating metastatic castration-resistant prostate cancer. [Formula 1] JPEG2026521901000005.jpg32155

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

The invention discloses a gene marker for predicting castration resistance and prognosis risk of hormone-sensitive prostate cancer, the gene marker comprises at least one of PRR7, REXO2, SKP1, MXD3, SPAG5, DHX16, NASP, TSPAN6, CCDC127 and BCAS1, and the gene marker is also used for constructing an evaluation model (LLPS-related prostate risk score, LPRS) for predicting castration resistance and prognosis risk of hormone-sensitive prostate cancer. The model can accurately predict castration resistance and death risk of hormone-sensitive prostate cancer, multi-factor Cox regression analysis finds that LPRS is an independent prognosis index of three prostate cancer queues, and further meta analysis results combine HR to 1.44 (95% CI = 1.11-1.89), that is, the risk of disease progression, recurrence or death is increased by 44% every time the LPRS is increased by one unit.

The invention relates to the technical field of biological medicine, and particularly discloses application of nefenavir. Nefinavir is used for preparing a medicine for treating or preventing castration-resistant prostate cancer, and the medicine can specifically up-regulate expression of DHCR7, induce DNA damage of tumor cells and activate a cell cycle arrest pathway mediated by periodic protein of the cells so as to inhibit key biological processes such as proliferation of the tumor cells, cholesterol metabolism and the like; especially, formation and amplification of multinuclear giant cells in castration-resistant prostate cancer can be effectively inhibited by up-regulating expression of DHCR7, so that malignant progression of multinuclear giant cell mediated tumors and treatment of drug resistance are blocked. Finally, the castration-resistant prostate cancer is prevented and treated, and the technical bottlenecks that an existing castration-resistant prostate cancer treatment means is limited in curative effect, and the drug resistance and metastasis capability mediated by multinuclear giant cells are difficult to inhibit in a targeted manner are solved.

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of metastatic castration-resistant prostate cancer and methods of increasing survival thereof.

The invention provides a blood diagnosis marker for identifying prostate cancer with good prognosis and metastatic castration-resistant prostate cancer and application of the blood diagnosis marker, and relates to the technical field of prostate cancer risk assessment. The blood diagnosis markers are NCKAP1, ERCC1, ZBTB46, PAQR7, ARMC8, PAQR8, LRRN4, NOG, LRRC47, CDKN2D, CLEC1B, STARD7 and ZSCAN2, and the blood diagnosis markers are used for diagnosis of the blood. The marker can be used for preparing a kit and a risk assessment chip for identifying prostate cancer with good prognosis and metastatic castration-resistant prostate cancer. According to the invention, the defects in the prior art are overcome, and a good and reliable basis is provided for identifying the prostate cancer with good prognosis and the metastatic castration-resistant prostate cancer by determining the blood diagnosis marker.

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.

The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of a PSMA-expressing cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the present disclosure comprise administering to a subject in need thereof a bispecific anti-PSMA x CD3 antibody as monotherapy or in combination with an anti-PD-1 antibody or a bispecific anti-PSMA x anti-CD28 antibody.

The present invention relates to methods for predicting the progression of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC), in an individual. The invention employs gene expression profiling combined with predictive modeling to assess the likelihood of overall survival and biochemical recurrence following treatment.

The present invention relates to a method of using taprazoparib or a pharmaceutically acceptable salt thereof in combination with enzalutamide or a pharmaceutically acceptable salt thereof for treating metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene mutations and increasing the survival thereof.

The present disclosure relates to methods of treating prostate cancer, including, for example, metastatic prostate cancer, castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer, in a subject in need thereof wherein the method comprises administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and further comprising the step of stopping or reducing the administration of a CYP3A inhibitor or inducer, an efflux transporter substrate or inhibitor, or an uptake transporter substrate or inhibitor to the subject prior to commencing administration of Compound A or a pharmaceutically acceptable salt thereof.

The application discloses castration-resistant prostate cancer nucleic acid aptamer and a screening method and application thereof, the nucleotide sequence of the aptamer comprises a DNA fragment shown in any one of sequence 1 or sequence 2; the aptamer has the advantages of small molecular weight, low immunogenicity, high affinity and the like; in addition, the screening technology adopted by the nucleic acid aptamer is low in cost, can be mass-produced in vitro, is good in repeatability, and is easy to transport and preserve; and the nucleic acid aptamer can be combined with castration-resistant prostate cancer tissue cells with high affinity and high specificity. The nucleic acid aptamer can be used to early detect the castration-resistant state of prostate cancer from the cellular and molecular level, and has important significance for timely adjusting prostate cancer medication and improving prognosis.

This document provides methods and materials for treating cancer (e.g., prostate cancer). For example, methods for using one or more agents that can regulate splicing of a nucleic acid (e.g., a precursor-messenger ribonucleic acid (pre-mRNA)) encoding one or more androgen receptor (AR) polypeptides to treat a mammal having prostate cancer (e.g., castration-resistant prostate cancer (CRPC)) are provided.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and / or androgen receptor expression.

Small molecule allosteric modulators of androgen receptor are disclosed. The compounds may inhibit androgen receptor coactivator recruitment, such as by preventing formation of protein-protein interaction (PPI) complexes and / or disrupting PPI complexes. A method of treating prostate cancer, such as castration-resistant prostate cancer, includes administering a small molecule allosteric modulator of androgen receptor.

The present disclosure relates to methods of treating prostate cancer, including prostate cancer comprising at least one somatic AR tumor mutation, in a subject, , for example, metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, progressive metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, metastatic castration-sensitive prostate cancer, prostate cancer that has not been treated with a novel hormone agent (NHA), metastatic prostate cancer that has not been treated with NHA; the present invention relates to methods of treating a castration-resistant prostate cancer, a castration-sensitive prostate cancer, a metastatic castration-resistant prostate cancer, and a metastatic castration-sensitive prostate cancer, where the methods comprise administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof. And a # imgabs0 # compound A.

This document provides methods and materials for treating cancer (e.g., prostate cancer). For example, methods for using one or more agents that can regulate splicing of a nucleic acid (e.g., a precursor-messenger ribonucleic acid (pre-mRNA)) encoding one or more androgen receptor (AR) polypeptides to treat a mammal having prostate cancer (e.g., castration-resistant prostate cancer (CRPC)) are provided.